| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,¶,||,¶
,¶
,¶
Departments of
*
Medicine,
Laboratory Medicine,
Immunology, and
Epidemiology, University of Washington, Seattle, WA 98195;
¶ Fred Hutchinson Cancer Research Center, Clinical Division, Seattle, WA 98109; and
||
Virginia Mason Research Center, Seattle, WA 98101
HSV-2 causes chronic infections. CD8 CTL may play several
protective roles, and stimulation of a CD8 response is a rational
element of vaccine design for this pathogen. The viral Ags recognized
by CD8 T cells are largely unknown. It has been hypothesized that HSV
inhibition of TAP may favor recognition of virion input proteins or
viral immediate early proteins. We tested this prediction using
HSV-specific CD8 CTL clones obtained from genital HSV-2 lesions. Drug
and replication block experiments were consistent with specificity for
the above-named classes of viral proteins. Fine specificity was
determined by expression cloning using molecular libraries of viral
DNA, and peptide epitopes recognized at nanomolar concentrations were
identified. Three of four clones recognized the viral tegument proteins
encoded by genes UL47 and UL49. These
proteins are transferred into the cytoplasm on virus entry. Processing
of the tegument Ag-derived epitopes was TAP dependent. The
tegument-specific CTL were able to lyse HLA class I-appropriate
fibroblasts after short times of infection. Lysis of keratinocytes
required longer infection and pretreatment with IFN-
. Another clone
recognized an immediate early protein, ICP0. Lymphocytes specific for
these lesion-defined epitopes could be reactivated from the PBMC of
additional subjects. These data are consistent with an influence of HSV
immune evasion genes upon the selection of proteins recognized by CD8
CTL in lesions. Tegument proteins, identified for the first time as Ags
recognized by HSV-specific CD8 CTL, are rational candidate vaccine
compounds.
This article has been cited by other articles:
|
|
 |
|
  L. Jing, D. H. Davies, T. M. Chong, S. Chun, C. L. McClurkan, J. Huang, B. T. Story, D. M. Molina, S. Hirst, P. L. Felgner, et al. An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling J. Virol., July 15, 2008; 82(14): 7120 - 7134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Koelle, A. Magaret, C. L. McClurkan, M. L. Remington, T. Warren, F. Teofilovici, and A. Wald Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects Clin. Vaccine Immunol., May 1, 2008; 15(5): 773 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Chentoufi, X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, M. Wu, X. Zhu, A. Mohebbi, S. Buus, et al. HLA-A*0201-Restricted CD8+ Cytotoxic T Lymphocyte Epitopes Identified from Herpes Simplex Virus Glycoprotein D J. Immunol., January 1, 2008; 180(1): 426 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bettahi, A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed Protective Immunity against Ocular Herpes Infection and Disease Induced by Highly Immunogenic Self-Adjuvanting Glycoprotein D Lipopeptide Vaccines Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4643 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jing, T. M. Chong, B. Byrd, C. L. McClurkan, J. Huang, B. T. Story, K. M. Dunkley, L. Aldaz-Carroll, R. J. Eisenberg, G. H. Cohen, et al. Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus J. Immunol., May 15, 2007; 178(10): 6374 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhu, D. M. Koelle, J. Cao, J. Vazquez, M. L. Huang, F. Hladik, A. Wald, and L. Corey Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation J. Exp. Med., March 19, 2007; 204(3): 595 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Diaz and D. M. Koelle Human CD4+ CD25high Cells Suppress Proliferative Memory Lymphocyte Responses to Herpes Simplex Virus Type 2. J. Virol., August 1, 2006; 80(16): 8271 - 8273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hosken, P. McGowan, A. Meier, D. M. Koelle, P. Sleath, F. Wagener, M. Elliott, K. Grabstein, C. Posavad, and L. Corey Diversity of the CD8+ T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes. J. Virol., June 1, 2006; 80(11): 5509 - 5515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jing, T. M. Chong, C. L. McClurkan, J. Huang, B. T. Story, and D. M. Koelle Diversity in the Acute CD8 T Cell Response to Vaccinia Virus in Humans J. Immunol., December 1, 2005; 175(11): 7550 - 7559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bosnjak, M. Miranda-Saksena, D. M. Koelle, R. A. Boadle, C. A. Jones, and A. L. Cunningham Herpes Simplex Virus Infection of Human Dendritic Cells Induces Apoptosis and Allows Cross-Presentation via Uninfected Dendritic Cells J. Immunol., February 15, 2005; 174(4): 2220 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Milligan, C.-F. Chu, C. G. Young, and L. R. Stanberry Effect of Candidate Vaginally-Applied Microbicide Compounds on Recognition of Antigen by CD4+ and CD8+ T Lymphocytes Biol Reprod, November 1, 2004; 71(5): 1638 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Koelle, Z. Liu, C. L. McClurkan, R. C. Cevallos, J. Vieira, N. A. Hosken, C. A. Meseda, D. C. Snow, A. Wald, and L. Corey Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor PNAS, October 28, 2003; 100(22): 12899 - 12904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Macdonald, A. W. Purcell, N. A. Mifsud, L. K. Ely, D. S. Williams, L. Chang, J. J. Gorman, C. S. Clements, L. Kjer-Nielsen, D. M. Koelle, et al. A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition J. Exp. Med., September 2, 2003; 198(5): 679 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. BenMohamed, G. Bertrand, C. D. McNamara, H. Gras-Masse, J. Hammer, S. L. Wechsler, and A. B. Nesburn Identification of Novel Immunodominant CD4+ Th1-Type T-Cell Peptide Epitopes from Herpes Simplex Virus Glycoprotein D That Confer Protective Immunity J. Virol., September 1, 2003; 77(17): 9463 - 9473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-X. Mbopi-Keou, L. Belec, J. Dalessio, J. Legoff, G. Gresenguet, P. Mayaud, D. W. G. Brown, and R. Ashley Morrow Cervicovaginal Neutralizing Antibodies to Herpes Simplex Virus (HSV) in Women Seropositive for HSV Types 1 and 2 Clin. Vaccine Immunol., May 1, 2003; 10(3): 388 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Koelle and L. Corey Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research Clin. Microbiol. Rev., January 1, 2003; 16(1): 96 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gierynska, U. Kumaraguru, S.-K. Eo, S. Lee, A. Krieg, and B. T. Rouse Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes J. Virol., June 5, 2002; 76(13): 6568 - 6576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Koelle, H. B. Chen, C. M. McClurkan, and E. W. Petersdorf Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles Blood, May 15, 2002; 99(10): 3844 - 3847. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
